<![CDATA[FDA Gives Accelerated Approval to Sevabertinib in HER2+ NSCLC ]]>
RegulatoryapprovedsevabertinibPositive
AI Analysis
Summary
The FDA granted accelerated approval to sevabertinib for metastatic non-squamous NSCLC with HER2 TKD activating mutations based on positive SOHO-01 trial results.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Accelerated approval granted based on SOHO-01 trial results
Importance:8/10
Sentiment:
0.90
FDA approvalaccelerated approvalNSCLCHER2+oncology
Read the original article
Published by Cancer Network on September 9, 2026 3:49 PM